

Nicole A De Weerd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6216666/publications.pdf>

Version: 2024-02-01

34
papers

2,331
citations

471371

17
h-index

454834

30
g-index

37
all docs

37
docs citations

37
times ranked

4495
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. <i>Cancer Discovery</i> , 2022, 12, 1560-1579.	7.7	13
2	Type I interferon antagonism of the JMJD3-IRF4 pathway modulates macrophage activation and polarization. <i>Cell Reports</i> , 2022, 39, 110719.	2.9	13
3	Cytokine Receptors and their Ligands. , 2022, , .		1
4	Structural integrity with functional plasticity: what type I IFN receptor polymorphisms reveal. <i>Journal of Leukocyte Biology</i> , 2020, 108, 909-924.	1.5	8
5	A structural "star" in interferon gamma signaling. <i>Immunology and Cell Biology</i> , 2019, 97, 442-444.	1.0	4
6	A proline deletion in IFNAR1 impairs IFN-signaling and underlies increased resistance to tuberculosis in humans. <i>Nature Communications</i> , 2018, 9, 85.	5.8	49
7	Defining the distinct, intrinsic properties of the novel type I interferon, IFN μ . <i>Journal of Biological Chemistry</i> , 2018, 293, 3168-3179.	1.6	32
8	Interferon epsilon promotes HIV restriction at multiple steps of viral replication. <i>Immunology and Cell Biology</i> , 2017, 95, 478-483.	1.0	33
9	Auto-phosphorylation Represses Protein Kinase R Activity. <i>Scientific Reports</i> , 2017, 7, 44340.	1.6	8
10	A hot spot on interferon β / β 2 receptor subunit 1 (IFNAR1) underpins its interaction with interferon- β 2 and dictates signaling. <i>Journal of Biological Chemistry</i> , 2017, 292, 7554-7565.	1.6	25
11	New Interferons. , 2016, , 501-508.		1
12	Cytokine Receptors and Their Ligands. , 2016, , 22-36.		0
13	Purification and biological characterization of soluble, recombinant mouse IFN β 2 expressed in insect cells. <i>Protein Expression and Purification</i> , 2014, 94, 7-14.	0.6	15
14	Structural basis of a unique interferon- β 2 signaling axis mediated via the receptor IFNAR1. <i>Nature Immunology</i> , 2013, 14, 901-907.	7.0	255
15	Interferon- μ Protects the Female Reproductive Tract from Viral and Bacterial Infection. <i>Science</i> , 2013, 339, 1088-1092.	6.0	197
16	Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. <i>Nature Medicine</i> , 2012, 18, 1224-1231.	15.2	406
17	The interferons and their receptors' distribution and regulation. <i>Immunology and Cell Biology</i> , 2012, 90, 483-491.	1.0	375
18	CS03-3. SOCS1 selectively regulates type I IFN signaling. <i>Cytokine</i> , 2011, 56, 8.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Type I-IFNs control GVHD and GVL responses after transplantation. <i>Blood</i> , 2011, 118, 3399-3409.	0.6	64
20	Suppressor of Cytokine Signaling (SOCS) 1 Inhibits Type I Interferon (IFN) Signaling via the Interferon $\hat{\pm}$ Receptor (IFNAR1)-associated Tyrosine Kinase Tyk2. <i>Journal of Biological Chemistry</i> , 2011, 286, 33811-33818.	1.6	128
21	A Conserved IFN- $\hat{\pm}$ Receptor Tyrosine Motif Directs the Biological Response to Type I IFNs. <i>Journal of Immunology</i> , 2008, 180, 5483-5489.	0.4	45
22	In Vitro Evaluation of Leukemia Inhibitory Factor Receptor Antagonists as Candidate Therapeutics for Inflammatory Arthritis. <i>Journal of Interferon and Cytokine Research</i> , 2007, 27, 281-290.	0.5	14
23	Type I Interferon Receptors: Biochemistry and Biological Functions. <i>Journal of Biological Chemistry</i> , 2007, 282, 20053-20057.	1.6	346
24	Generation of mutant leukaemia inhibitory factor (LIF) $\hat{\pm}$ IgG heavy chain fusion proteins as bivalent antagonists of LIF. <i>Journal of Immunological Methods</i> , 2007, 323, 1-10.	0.6	6
25	Molecular Characterization of Polygalacturonases as Grass Pollen-Specific Marker Allergens: Expulsion from Pollen via Submicronic Respirable Particles. <i>Journal of Immunology</i> , 2004, 172, 6490-6500.	0.4	50
26	Effect of cysteine mutagenesis on human IgE reactivity of recombinant forms of the major rye grass pollen allergen Lol p 1. <i>Allergy International</i> , 2003, 52, 183-190.	1.4	6
27	Oral Immunization with a Recombinant Major Grass Pollen Allergen Induces Blocking Antibodies in Mice. <i>International Archives of Allergy and Immunology</i> , 2003, 130, 119-124.	0.9	10
28	Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. <i>European Journal of Immunology</i> , 2002, 32, 270-280.	1.6	76
29	Title is missing!. <i>Aerobiologia</i> , 2002, 18, 87-106.	0.7	24
30	Hypoallergenic Forms of the Ryegrass Pollen Allergen Lol p 5 as Candidates for Immunotherapy. <i>International Archives of Allergy and Immunology</i> , 2001, 124, 380-382.	0.9	5
31	Genetically Engineered Plant Allergens with Reduced Anaphylactic Activity. <i>International Archives of Allergy and Immunology</i> , 1999, 119, 75-85.	0.9	43
32	In vitro propagation of cauliflower, <i>Brassica oleracea</i> var. botrytis for hybrid seed production. <i>Plant Cell, Tissue and Organ Culture</i> , 1999, 56, 89-95.	1.2	15
33	<i>Agrobacterium tumefaciens</i> -mediated transformation of cauliflower, <i>Brassica oleracea</i> var. botrytis. <i>Molecular Breeding</i> , 1998, 4, 531-541.	1.0	49
34	Comparison of shoot regeneration potential from seedling explants of Australian cauliflower (<i>Brassica oleracea</i> var. botrytis) varieties. <i>Australian Journal of Agricultural Research</i> , 1998, 49, 1261.	1.5	15